Trial · NCT03255018
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Complete Response | 50 | percentage of participants | |
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Complete Response | 0 | percentage of participants | |
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Unconfirmed Complete Response | 0 | percentage of participants | |
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Unconfirmed Complete Response | 0 | percentage of participants | |
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Partial Response | 0 | percentage of participants | |
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Partial Response | 11 | percentage of participants | |
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Progressive Disease | 50 | percentage of participants | |
| Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Progressive Disease | 89 | percentage of participants | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Grade 1 | 5 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Grade 1 | 35 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Grade 2 | 0 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Grade 2 | 20 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Grade 3 | 0 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Grade 3 | 8 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Grade 4 | 0 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Grade 4 | 2 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 1 Gray-Zone Lymphoma (GZL) | Grade 5 | 0 | adverse events | |
| Number of Grades 1-5 Adverse Events in Participant With Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL) | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Grade 5 | 0 | adverse events | |
| Best Overall Response Rate According to the 5-point Lugano Classification for Interpreting 18 F-fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Scans | Cohort 1 Gray-Zone Lymphoma (GZL) | Complete Response | 100 | percentage of participants | |
| Best Overall Response Rate According to the 5-point Lugano Classification for Interpreting 18 F-fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Scans | Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL) | Complete Response | 0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03255018/results